Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.47 | -10.2396514161 | 4.59 | 4.59 | 3.78 | 4979 | 4.14622349 | CS |
4 | -0.98 | -19.2156862745 | 5.1 | 5.2 | 3.78 | 2515 | 4.41395269 | CS |
12 | -0.86 | -17.2690763052 | 4.98 | 5.85 | 3.78 | 1751 | 4.78673668 | CS |
26 | -4.28 | -50.9523809524 | 8.4 | 9 | 3.78 | 1830 | 5.20014146 | CS |
52 | -4.28 | -50.9523809524 | 8.4 | 9 | 3.78 | 1830 | 5.20014146 | CS |
156 | -4.28 | -50.9523809524 | 8.4 | 9 | 3.78 | 1830 | 5.20014146 | CS |
260 | -4.28 | -50.9523809524 | 8.4 | 9 | 3.78 | 1830 | 5.20014146 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.